Thioridazine treatment prevents cardiopathy in Trypanosoma cruzi infected mice.

LO PRESTI MS, RIVAROLA HW, BUSTAMANTE JM, FERNÁNDEZ AR, ENDERS JE, FRETES R, GEA

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Año: 2004 p. 634 - 634

0924-8579

rypanosoma cruzi trypanothione reductase is an enzyme that has been identifiedas a potential target for chemotherapy. Thioridazine inhibits it and preventedcardiopathy in mice infected with T. cruzi Tulahuen strain. As not all T. cruzistrains respond to treatment in the same way, an isolate from a chronic patient(SGO Z12) was used; parasitaemias were studied along with, survival, serology,electrocardiography, histology and cardiac beta receptor function. Parasitaemiain thioridazine (80 mg/(kg day) for 3 days) treated mice was less and lasted for a shorter period (P < 0.01), there were reduced electrocardiographic andhistological alterations and significantly improved survival (80% of non-treated died). Treated mice had lower receptor affinity and higher density as acompensatory mechanism, modifying the course of T. cruzi infection (SGO Z12isolate) and preventing the consequent cardiopathy. Copyright 2004 Elsevier B.V